1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

SFOSF
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.US flagOther OTC
2.18
USD
- -
- -
5.76BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.48
5.24
5.48
6.31
7.53
9.85
11.19
11.83
15.26
16.85
15.44
15.42
15.7
15.21
Basic EPS, GAAP
0.71
0.92
1.07
1.21
1.27
1.07
1.3
1.43
1.85
1.43
0.89
1.04
1.27
1.23
Free Cash Flow per Basic Share
-0.01
0.04
0.17
0.08
0.17
-0.09
-0.29
-0.73
-0.4
-0.64
-0.72
0.03
0.29
-1.66
Dividend per Share
0.36
0.42
0.48
0.51
0.58
0.7
0.73
0.72
0.75
0.91
0.92
0.77
0.73
0.76
Book Value per Share
2.86
3.38
4.02
4.92
5.53
6.06
6.92
7.83
9.23
9.92
10.15
10.97
11.96
11.41
Tangible Book Value per Share
5.41
5.63
6.14
7.82
5.29
6.14
7.52
10.08
9.99
10.67
10.59
11.15
11.71
11.31
Basic Weighted Avg Shares
2,229
2,297
2,299
2,319
2,460
2,531
2,555
2,561
2,556
2,609
2,681
2,663
2,654
2,637
Sales/Revenue/Turnover
9,996
12,026
12,609
14,629
18,534
24,918
28,585
30,307
39,011
43,952
41,400
41,067
41,662
40,119
Operating Margin (%)
11.14
9.92
11.69
11.91
12.43
9.5
9.15
9.34
6.95
8.27
3.78
7.8
7.55
7.05
Depreciation Expense
416
558
649
733
939
1,320
1,472
1,666
1,834
2,336
2,965
3,002
3,513
- -
Net Income, GAAP
1,583
2,113
2,460
2,806
3,124
2,708
3,322
3,663
4,729
3,731
2,386
2,770
3,371
3,247
Effective Tax Rate (%)
15.48
12.81
14.86
9.81
11.73
15.64
17.28
15.77
17.65
13.7
11.32
15.75
16.9
18.03
Profit Margin (%)
15.83
17.57
19.51
19.18
16.86
10.87
11.62
12.09
12.12
8.49
5.76
6.74
8.09
8.09
Working Capital
1,708
-873
-2,614
656
-1,544
78
2,970
212
1,118
1,981
35
-2,962
-2,604
-1,681
LT Debt
4,200
3,857
3,572
5,571
9,815
12,996
12,987
9,103
9,697
12,845
15,555
12,985
14,913
14,349
Total Equity
17,665
19,103
20,670
25,250
29,741
33,593
39,204
45,984
48,380
54,109
56,616
59,934
61,840
60,315
Return on Invested Capital (%)
4.27
4.1
4.24
4.57
4.66
3.7
3.63
3.61
3.11
3.97
1.57
2.87
2.66
2.42
Return on Capital (%)
10.32
13.71
12.05
11.71
9.92
7.66
8.27
8.26
9.37
7.08
4.39
4.27
4.4
4.61
Return on Common Equity (%)
22.09
29.85
28.91
27.16
24.98
18.71
20.12
19.4
21.66
15.08
8.99
9.82
11.06
11.24

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
23,173
22,059
22,645
LT Borrowings
10,444
11,560
11,595
LT Finance Leases
2,542
2,629
2,754
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2,671
2,671
2,670
Market Capitalization
34,841
37,328
37,038

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
34,491
34,439
34,342
Cash, Cash Equivalents & STI
16,120
16,070
15,639
Accounts Receivable, Net
7,952
7,857
8,481
Inventories
7,259
6,823
6,744
Total Current Liabilities
37,453
35,501
36,023
Payables & Accruals
- -
- -
- -
ST Debt
23,173
22,059
22,645
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.76%
6.14%
3.18%
Free Cash Flow
126.56%
194.76%
1,045.04%
Net Income, GAAP
5.47%
1.95%
21.69%
Sales/Revenue/Turnover
13.41%
7.24%
1.45%
Total Cash Common Dividend
6.51%
2.02%
-5.57%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,157
10,306
10,449
10,155
41,067
2025
9,420
10,094
12,268
- -
41,662
2026
10,073
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
- -
- -
- -
1.04
2025
0.29
- -
- -
- -
1.27
2026
0.33
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
- -
- -
- -
0.77
2025
0.11
- -
- -
- -
0.73
2026
0.09
- -
- -
- -
- -

Company Description

APIChat
CEO
Yi Liu
Full Time Employees
40,557
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Building A Shanghai People's Republic of China 200233
IPO Date
Apr 21, 2014
Website
fosunpharma.com
Similar Companies
Harbin Pharmaceutical Group Co., Ltd. (600664.SS)
Sequent Scientific Limited (SEQUENT.NS)
Lee's Pharmaceutical Holdings Limited (0950.HK)
Gage Growth Corp. (GAEGF)
MGC Pharmaceuticals Limited (MXC.AX)
Toho Holdings Co., Ltd. (8129.T)
Business
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global healthcare enterprise, driven by innovation, with extensive operations spanning both domestic and international markets. The company's core activities encompass several key areas, including pharmaceutical manufacturing, advanced medical devices and diagnostics, comprehensive healthcare services, and an extensive network for pharmaceutical distribution and retail. Fosun Pharma focuses its pharmaceutical efforts on critical therapeutic domains such as oncology, immune-inflammatory conditions, metabolic and digestive disorders, central nervous system afflictions, and anti-infective treatments. This includes the development and commercialization of innovator drugs, biosimilars, and vaccines, with notable products like their anti-malaria injectable, pioneering CAR-T cell therapies, and advanced monoclonal antibodies targeting various cancers. In medical technology, it provides high-value devices and diagnostic solutions. Beyond products, the company manages hospitals and clinics, offering a spectrum of healthcare and specialized disease management services. Additionally, through strategic collaborations, it sustains a robust business in the wholesale and retail of medical supplies. Established in Shanghai, China, in 1994, Fosun Pharma has continuously emphasized its "4IN" strategy—Innovation, Internationalization, Intelligentization, and Integration—to address unmet clinical needs worldwide and expand its global footprint.

Company News

APIChat

  • defenseworld.net

    Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (OTCMKTS:SFOSF) Short Interest Up 21.2% in January

  • reuters.com

    Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

  • forbes.com

    Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

  • seekingalpha.com

    Week In Review: Nuance In-Licenses RSV Vaccine In $225 Million Deal

  • seekingalpha.com

    Pandemic Accelerates China's Drive Into mRNA Treatments

  • seekingalpha.com

    Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

  • seekingalpha.com

    Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal